Episodes of acute agitation associated with schizophrenia and bipolar disorder pose treatment and economic challenges for patients and staff, including higher health care utilization, medical costs, and patient mortality risk. Detailing and quantifying these clinical and economic challenges can assist in evaluating the current therapeutic paradigms and selecting effective and safe treatment options, which may improve patient outcomes and lower staff burden.